IsoRay (ISR) Receives Final Washington State Approval for GliaSite

IsoRay, Inc. (Amex: ISR) has received final approval from the State of Washington Department of Health to manufacture its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer. In conjunction with the previously announced FDA clearance, the Washington State approval represents IsoRay’s final regulatory hurdle to commence the sale of its GliaSite brain cancer treatment in the United States. GliaSite® is a landmark technology that allows physicians to treat more brain cancer patients than ever before with internal radiation or brachytherapy.

The GliaSite® radiation system offers a number of advantages in brain cancer treatment. A specified high dose of a liquid radiation source is placed in the areas most likely to contain cancer after brain tumor removal. This form of radiation is less likely to damage healthy brain tissue than other alternatives. The ability for the tumor to recur is greatly diminished, impacting patient longevity and quality of life.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Quantum BioPharma gets FDA clearance for MS drug phase 2 trial
• FingerMotion reports $5.1M cash, 30% burn cut under new team
• Bonk Inc. redeems $4M in preferred stock, waives anti-dilution rights